Yd Bio Limited · NASDAQ:YDES
Yd Bio — Investor Presentation (January 2026)
26 slides from Yd Bio's investor presentation, Jan 15, 2026
Slide 1: YD Bio Limited: Architecting the Modern Biotechnology Ecosystem
: YDES 1 YD Bio Limited: Architecting the Modern Biotechnology Ecosystem Investment Deck January 2026
Slide 2: Forward-looking Statements
Forward - looking Statements 2 This presentation contains forward - looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this presentation other than statements of historical fact, in
Slide 3: 3
3
Slide 4: An Investment in a New Biotech Paradigm
An Investment in a New Biotech Paradigm An integrated, execution - capable ecosystem designed for scalable value creation. 4 Commercial Anchor with Validated Evidence A diagnostics platform supported by reported validation data, generating recurring revenue and licensing opportunities. 1. 2. 3. 4. 5
Slide 5: Foundation & Global Partnerships timeline
2013 – 2015 Foundation & Global Partnerships Regulated Distribution & Consumer Health Origins Established regulated operations supporting clinical trial drug supply and launched a compliance - first consumer health and supplement business. Global Partner Expansion Expanded service footprint and beca
Slide 6: Mission, Vision and Values
MISSION We build scalable healthcare platforms designed to accelerate the translation of innovation into real - world impact through disciplined execution and trusted partnerships. 6 6 VISION We envision precision health powered by interoperable platforms — connecting early detection, evidence gener
Slide 7: Four scalable platforms
YD Bio is building four scalable platforms — Regulated Diagnostics, Life Science Distribution & Services, Ocular Health Commercialization and Shared Commercialization Engine — designed for partner - driven B2B growth. 7 7
Slide 8: The Architect's Blueprint
The Architect’s Blueprint Our strategic acquisitions and partnerships are structured as components of an integrated platform intended to internalize execution, improve operating predictability, and reduce reliance on fragmented external vendors. Diagnostics & Data Engine (EG BioMed) 8 Confidential &
Slide 9: The Flywheel Effect: A Self-Reinforcing Engine for Sustainable Growth
The Flywheel Effect: A Self - Reinforcing Engine for Sustainable Growth This integrated model is designed to create a virtuous cycle where platform performance supports further execution capabilities, enabling scalable, capital - efficient growth across programs and partnerships. Advanced Diagnostic
Slide 10: Strategic M&A: Building Capabilities for End-to-End Execution
Strategic MGA: Building Capabilities for End - to - End Execution 10 Confidential & Proprietary — © YD Bio Limited. Do not distribute Expected Strategic Impact Core Contribution Status Acquisition Target Component Forms the upstream data and revenue engine; anchors oncology strategy in early detecti
Slide 11: Our Vision for 2030
Our Vision for 2030: Confidential & Proprietary — © YD Bio Limited. Do not distribute A U.S. - Anchored, Globally Integrated Biotechnology Platform Based on our ecosystem strategy, YD Bio aims to become an execution - capable platform defined by: x U.S. Operational Leadership: Strengthened FDA engag
Slide 12: Our Core Platforms & Commercial Offerings
Our Core Platforms & Commercial Offerings Regulated Diagnostics Platform (LDT - First) In partnership with EG BioMed, we are building a U.S. - based clinical laboratory strategy focused on DNA methylation – driven oncology testing and clinical evidence generation. ● LDT - first commercialization des
Slide 13: Platforms, Products & Revenue Engines
Platforms, Products & Revenue Engines Diversified commercial engines today with regulated and investigational optionality over time. Confidential & Proprietary — © YD Bio Limited. Do not distribute
Slide 14: Regulated Diagnostics Platform — LDT Portfolio & Evidence Roadmap
Regulated Diagnostics Platform — LDT Portfolio & Evidence Roadmap A scalable LDT - first oncology testing portfolio delivered through a partner CAP - accredited, CLIA - certified laboratory, designed for enterprise adoption and B2B licensing expansion. Confidential & Proprietary — © YD Bio Limited.
Slide 15: U.S. Commercial Footprint — Coverage & Operational Readiness
U.S. Commercial Footprint — Coverage & Operational Readiness 15 Testing services are delivered through a partner CAP - accredited, CLIA - certified laboratory with established logistics and reporting workflows. Effective Coverage • Sample collection and testing services currently supported across 44
Slide 16: Ocular Health Commercial Portfolio
Ocular Health Commercial Portfolio An eye care commercialization platform with established product categories and scalable distribution capabilities. Commercial Portfolio Artificial Tears (OTC) Preservative - free lubricating eye drops formulated to support ocular comfort for patients experiencing m
Slide 17: Investigational Exosome Therapeutics Platform (LSC Programs)
Investigational Exosome Therapeutics Platform (LSC Programs) Partner - led limbal stem cell (LSC) exosome programs being explored as investigational approaches for ocular surface and regenerative medicine applications. 17 Confidential & Proprietary — © YD Bio Limited. Do not distribute Program Focus
Slide 18: Wellness Commercialization Platform (Supplements & Consumer Health)
Wellness Commercialization Platform (Supplements & Consumer Health) A compliance - first consumer health channel supporting recurring revenue, partner product onboarding, and scalable commercialization capabilities. Regulatory & Compliance - First Formulation & Product Design Quality - Controlled Ma
Slide 19: Life Science Distribution & Clinical Trial Supply Chain Platform
We provide compliant, end - to - end clinical trial supply chain and distribution services — supporting biopharma, CROs, and research institutions with reliable global execution. Life Science Distribution & Clinical Trial Supply Chain Platform Compliant Sourcing Multi - Region Distribution Quality &
Slide 20: U.S. Hub Strategy: Planned California Operations Center
U.S. Hub Strategy: Planned California Operations Center This planned center is intended to strengthen FDA engagement, support clinical execution, and expand U.S. market access. It is expected to be activated in phases, aligning investment with operational milestones to maintain capital discipline. C
Slide 21: Our Leadership Team
Our Leadership Team Our leadership team combines scientific expertise, global industry experience, and operational execution across regulated healthcare markets. Bachelor of Science in Accounting and Finance University of East Anglia, UK Ethan Shen, PhD Chairman/CEO Ph.D. of Translational Medicine,
Slide 22: We Are Building Scalable Platforms in Large, High-Need Global Markets
We Are Building Scalable Platforms in Large, High - Need Global Markets YD Bio operates across regulated diagnostics, ocular health commercialization, and life science services — addressing durable demand drivers and designed to create multiple pathways to scale through partner - led execution. Conf
Slide 23: Financials: Net Revenue by sales categories
Financials Net Revenue ($) by sales categories Fiscal Years Ended December 31, 2023 and 2024 For the year ended December 31, 2024, revenue was derived primarily from the sale of medical and related products, which accounted for 57.4%. Sales of drugs contributed 28.1%, nutritional products made up 8.
Slide 24: Financials: Gross Profit
Financials Gross Profit ($) Fiscal Years Ended December 31, 2023 and 2024 (in thousands) For the years ended December 31, 2023 and 2024, gross profits were $153,445 and $155,356, respectively. 24 Confidential & Proprietary — © YD Bio Limited. Do not distribute
Slide 25: Building a Scalable Global Life Science Platform
Building a Scalable Global Life Science Platform 25 Confidential & Proprietary — © YD Bio Limited. Do not distribute Partner - led innovation, compliance - first execution, and diversified commercialization engines across regulated diagnostics, ocular health, and life science services . Large, Durab
Slide 26: Thank You
Thank You For investor inquiries, please contact: investor@ydesgroup.com Investor Relations WFS Investor Relations Inc. (WFS) services@wealthfsllc.com Auditor: MaloneBailey LLP Legal Counsel: Winston & Strawn, LLP ydesgroup.com